Everyone responds different to disease and treatment. We are working to understand how. Please visit our website to find out more and apply for our open positions.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

PDS BIOTECH REPORTS AN INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

PDS Biotechnology Corporation | December 27, 2021

news image

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, announced that the compensation committee of the board of directors of the Company approved, on December 20, 2021, an equity award to Michael Lalond, the Company’s new Director of Quality Assurance, as a material inducement to Mr. Lalond entering into employment with PDS ...

Read More

PROVENTION BIO AND VACTECH ANNOUNCE PUBLICATION OF PROOF-OF-CONCEPT DATA FOR COXSACKIEVIRUS B VACCINE

Provention Bio, Inc. | May 19, 2020

news image

The preclinical prototype vaccine is well-tolerated and provides strong protection against coxsackievirus B infections and diabetes in relevant animal models. Results provide a solid scientific basis for human trials with Provention's PRV-101 vaccine. Read More

PHARMA MAR STARTS APLICOV-PC CLINICAL TRIAL WITH APLIDIN FOR TREATMENT OF COVID-19

PharmaMar | April 28, 2020

news image

PharmaMar (MSE: PHM) has announced the start of the APLICOV-PC clinical trial with Aplidin® (plitidepsin), for the treatment of patients with COVID-19, which has been authorized by the Spanish Medicines and Healthcare Products Agency (AEMPS). This is a multicenter, randomized, parallel, open-label study to evaluate the safety profile and efficacy of three doses of plitidepsin in patients with COVID-19 requiring hospital admission. Three hospitals from Madrid (Spain) will participate in the s...

Read More

INDUSTRIAL IMPACT

ALLOY THERAPEUTICS RAISES $42 MILLION SERIES D FINANCING TO ACCELERATE DISCOVERY TECHNOLOGY DEVELOPMENT ACROSS BIOLOGIC MODALITIES

Alloy Therapeutics, Inc. | October 04, 2022

news image

Alloy Therapeutics, a biotechnology ecosystem company, has closed $42 million in Series D financing led by its existing investors 8VC and Mubadala Capital and joined by return investors Thiel Capital, Presight Capital, Founders Fund, and other unnamed family offices and sovereign wealth funds. Alloy will use proceeds from the Series D financing to further support the drug discovery community with new pre-competitive drug discovery technologies in new biologic modalities and new partnership model...

Read More
news image

CELL AND GENE THERAPY

PDS BIOTECH REPORTS AN INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

PDS Biotechnology Corporation | December 27, 2021

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, announced that the compensation committee of the board of directors of the Company approved, on December 20, 2021, an equity award to Michael Lalond, the Company’s new Director of Quality Assurance, as a material inducement to Mr. Lalond entering into employment with PDS ...

Read More
news image

PROVENTION BIO AND VACTECH ANNOUNCE PUBLICATION OF PROOF-OF-CONCEPT DATA FOR COXSACKIEVIRUS B VACCINE

Provention Bio, Inc. | May 19, 2020

The preclinical prototype vaccine is well-tolerated and provides strong protection against coxsackievirus B infections and diabetes in relevant animal models. Results provide a solid scientific basis for human trials with Provention's PRV-101 vaccine. Read More

news image

PHARMA MAR STARTS APLICOV-PC CLINICAL TRIAL WITH APLIDIN FOR TREATMENT OF COVID-19

PharmaMar | April 28, 2020

PharmaMar (MSE: PHM) has announced the start of the APLICOV-PC clinical trial with Aplidin® (plitidepsin), for the treatment of patients with COVID-19, which has been authorized by the Spanish Medicines and Healthcare Products Agency (AEMPS). This is a multicenter, randomized, parallel, open-label study to evaluate the safety profile and efficacy of three doses of plitidepsin in patients with COVID-19 requiring hospital admission. Three hospitals from Madrid (Spain) will participate in the s...

Read More
news image

INDUSTRIAL IMPACT

ALLOY THERAPEUTICS RAISES $42 MILLION SERIES D FINANCING TO ACCELERATE DISCOVERY TECHNOLOGY DEVELOPMENT ACROSS BIOLOGIC MODALITIES

Alloy Therapeutics, Inc. | October 04, 2022

Alloy Therapeutics, a biotechnology ecosystem company, has closed $42 million in Series D financing led by its existing investors 8VC and Mubadala Capital and joined by return investors Thiel Capital, Presight Capital, Founders Fund, and other unnamed family offices and sovereign wealth funds. Alloy will use proceeds from the Series D financing to further support the drug discovery community with new pre-competitive drug discovery technologies in new biologic modalities and new partnership model...

Read More